Mochamad Yusuf Alsagaff, - and Eka Prasetya Budi Mulia, - (2021) Hypertension and COVID-19: Potential use of beta-blockers and a call for Randomized Evidence. Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence, 73 (6). pp. 757-759. ISSN 0019-4832

	Text (Artikel) 1. Hypertension and COVID-19 Potential use of beta-blockers and a call for evidenc_IHJ 2021.pdf Download (173kB)
	Text (Karil) karil 1.pdf Download (96kB)
	Text (Bukti Korespondensi) 1. Korespondensi.pdf Download (101kB)
	Text (Similariti) 1. Turnitin.pdf Download (870kB)

Abstract

Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in COVID-19 treatment, with current evidence of the potential mechanism of beta-blockers remains scarce. However, several mechanisms were suggested, including decreasing RAAS pathway activity and lowering the ACE2 levels, reducing cytokine storms, and may be beneficial in reducing mortality in ARDS related COVID-19. Further large-scale randomized clinical trials should be conducted before a definite recommendation can be drawn.

Actions (login required)

View Item